Clinical Trial: A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CD-001 in Patients with Advanced Solid Tumors

U.S., Jan. 31 -- ClinicalTrials.gov registry received information related to the study (NCT06801470) titled 'A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CD-001 in Patients with Advanced Solid Tumors' on Jan. 21.

Brief Summary: To assess the safety, tolerability, PK and preliminary efficacy of CD-001 in patients with advanced solid tumors. and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).

Study Start Date: Jan. 08

Study Type: INTERVENTIONAL

Condition: Advanced Solid Tumors

Intervention: DRUG: CD-001

CD-001 administered as an intravenous (IV) infusion.

Recruitment Status: ENROLLING_BY_INVITATION

Sponsor: CD (Suzhou) Biopharma Co., Ltd.

Disclaimer:...